Literature DB >> 207825

Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications.

A K Lefvert, K Bergström, G Matell, P O Osterman, R Pirskanen.   

Abstract

Antibodies to cholinergic receptor structures were found in 75% of 76 Finnish and 93% of 175 Swedish patients with myasthenia gravis. The amount of antibodies showed a positive correlation to the severity of the disease, and was reduced during immunosuppressive treatment, and by thymectomy. Thymoma patients had high values. The antibody was also found in the cerebrospinal fluid. Two healthy newborn babies of myasthenic mothers had antibodies during the first weeks of life, in spite of no clinical symptoms. The occurrence of IgM antibodies before IgM antibodies in two patients during the early stages of myasthenia gravis suggests that the antibody is not a primary cause of the disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207825      PMCID: PMC493044          DOI: 10.1136/jnnp.41.5.394

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Acetylcholine receptor antibodies in myasthenia gravis.

Authors:  S H Appel; R R Almon; N Levy
Journal:  N Engl J Med       Date:  1975-10-09       Impact factor: 91.245

2.  STUDIES IN MYASTHENIA GRAVIS. 1. A CLINICAL STUDY OF 180 PATIENTS.

Authors:  H J OOSTERHUIS
Journal:  J Neurol Sci       Date:  1964 Nov-Dec       Impact factor: 3.181

3.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

4.  Studies in neuromuscular function. IV. Stimulating and depressant effects of acetylcholine and choline in patients with myasthenia gravis, and their relationship to the defect in neuromuscular transmission.

Authors:  D GROB; A M HARVEY; R J JOHNS
Journal:  Bull Johns Hopkins Hosp       Date:  1956-09

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  The effect of thoracic duct lymph drainage in myasthenia gravis.

Authors:  K Bergström; C Franksson; G Matell; G von Reis
Journal:  Eur Neurol       Date:  1973       Impact factor: 1.710

7.  Acetylcholine-receptor antibodies in cerebrospinal fluid of patients with myasthenia gravis.

Authors:  A K Lefvert; R Pirskanen
Journal:  Lancet       Date:  1977-08-13       Impact factor: 79.321

8.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

9.  Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection.

Authors:  W Strober; R D Wochner; P P Carbone; T A Waldmann
Journal:  J Clin Invest       Date:  1967-10       Impact factor: 14.808

10.  An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.

Authors:  J Lindstrom
Journal:  Clin Immunol Immunopathol       Date:  1977-01
View more
  53 in total

Review 1.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.

Authors:  Y Nemoto; S Kuwabara; S Misawa; N Kawaguchi; T Hattori; M Takamori; A Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

Review 3.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

5.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

6.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

7.  Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

Authors:  A Rødgaard; F C Nielsen; R Djurup; F Somnier; S Gammeltoft
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

8.  The diagnosis of thymoma in myasthenia gravis.

Authors:  J A Aarli
Journal:  Ital J Neurol Sci       Date:  1983-12

9.  Differences in the interaction of acetylcholine receptor antibodies with receptor from normal, denervated and myasthenic human muscle.

Authors:  A K Lefvert
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-01       Impact factor: 10.154

10.  Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor.

Authors:  C M Gomez; R L Wollmann; D P Richman
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.